Noxopharm Limited Stock Z Score
NOXOF Stock | USD 0.03 0.00 0.00% |
Noxopharm |
Noxopharm Limited Company Z Score Analysis
Noxopharm's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
Based on the company's disclosures, Noxopharm Limited has a Z Score of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The z score for all United States stocks is 100.0% higher than that of the company.
Noxopharm Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Noxopharm's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Noxopharm could also be used in its relative valuation, which is a method of valuing Noxopharm by comparing valuation metrics of similar companies.Noxopharm is currently under evaluation in z score category among related companies.
Noxopharm Fundamentals
Return On Equity | -0.58 | |||
Return On Asset | -0.16 | |||
Operating Margin | (1.80) % | |||
Current Valuation | 22.3 M | |||
Shares Outstanding | 292.24 M | |||
Shares Owned By Insiders | 33.53 % | |||
Shares Owned By Institutions | 1.00 % | |||
Price To Book | 2.36 X | |||
Price To Sales | 7.11 X | |||
Revenue | 5.43 M | |||
Gross Profit | (2.35 M) | |||
EBITDA | (18.33 M) | |||
Net Income | (18.67 M) | |||
Cash And Equivalents | 14.01 M | |||
Cash Per Share | 0.05 X | |||
Total Debt | 160.62 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 9.13 X | |||
Book Value Per Share | 0.08 X | |||
Cash Flow From Operations | (13.73 M) | |||
Earnings Per Share | (0.03) X | |||
Beta | 1.25 | |||
Market Capitalization | 38.58 M | |||
Total Asset | 26.59 M | |||
Net Asset | 26.59 M |
About Noxopharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Noxopharm Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Noxopharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Noxopharm Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Noxopharm Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Noxopharm Pink Sheet analysis
When running Noxopharm's price analysis, check to measure Noxopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Noxopharm is operating at the current time. Most of Noxopharm's value examination focuses on studying past and present price action to predict the probability of Noxopharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Noxopharm's price. Additionally, you may evaluate how the addition of Noxopharm to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |